Efficacy of conservative treatment in patients with dry form of age-related macular degeneration

Kovalevskaya, M. A.; Milyutkina, S

doi:10.17116/oftalma2015131281-88

Cited by 3 publications

(1 citation statement)

References 12 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients diagnosed with AMD, an Amsler grid [12] should be used, in order to check on a weekly basis if they observe any changes on it, so as to seek professional opinion if they do. The progress of the disease should also be closely monitored by an ophthalmologist every 3-6 months.…”

Section: Introductionmentioning

confidence: 99%

Fundus autofluorescence and multicolour imaging comparison in assessing disease severity in patients suffering from geographic atrophy. A case series analysis

Mallias

Mylova²,

Tassiopoulou³

2017

Ophthalmology J

View full text Add to dashboard Cite

introduCtion. The aim of the study is to determine which depicting modality, fundus autofluorescence or multicolour imaging, is a better diagnostic tool in the monitoring of the progression of geographic atrophy in patients with severe dry macular degeneration. MateriaL and Methods. Fifty patients (93 eyes) participated in this study. OCT examination (Spectralis HRA + OCT, Heidelberg Engineering, Germany) was performed in order to confirm that they fit the criteria to proceed in the study. In all patients, fundus autofluorescence and multicolour imaging was performed. resuLts. The area of geographic atrophy was depicted with both modalities and useful information was obtained. In some cases, multicolour imaging provided more useful clues and in other cases the fundus autofluorescence provided useful information for the progression of the disease. ConCLusions. Both modalities provide a wide range of useful information about the progression of geographic atrophy in patients with severe dry age-related macular degeneration and should both be performed in order to gather all the useful information about the disease progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Fundus autofluorescence and multicolour imaging comparison in assessing disease severity in patients suffering from geographic atrophy. A case series analysis

Mallias

Mylova²,

Tassiopoulou³

2017

Ophthalmology J

View full text Add to dashboard Cite

show abstract

Our Experience of Nutraceutical Effects in Age-Related Macular Degeneration

et al. 2020

View full text Add to dashboard Cite

Purpose: to assess the possibilities of ophthalmonutraceuticals using in age-related macular degeneration (AND) patients.Patients Methods. The study included 35 patients (68.3 ± 6.3 years old; 15 men, 20 women) with AMD (AREDS-2 and AREDS-3 categories). As an ophthalmic nutraceutical, a biological active supplement was used, included vitamins C and E, zinc, lutein, zeaxantine, cooper, selenium (Retinorm; 3 capsules per day with meals). The observation period was 12 months (6 courses of therapy). There were the main control points: examination at study entry and examination at study completion. All those observed patients were underwent standard ophthalmological examination; fundus state photo registration (Nidek); OCT (Opto-Vue). The significance of a possible increase in the proportion of AREDS-3–4 AMD category patients was assessed using the Pearson γ2 test. An additional criterion was the maximum corrected visual acuity (MCVA) stabilization. The mean and its standard deviation (M ± s) were calculated, the significance of differences was assessed using the Wilcoxon’s t-test.Results. The study was completed in 33 patients. In 2 eyes a transition of AMD from the AREDS-2 to AREDS-3 category was recorded (an increase in the number and size of druses, with the appearance of large druses). The increase in the proportion of patients with the AREDS-3 AMD category was statistically insignificant (γ2 = 0.267; p = 0.606). In no case was there a transition to the AREDS-4 category. In the vast majority of those who completed the study (31 eyes; 93.9 %), the manifestations of AMD were stable, which, taking in account the chosen criterion, allows us to consider nutraceutical support to be affective. MCVA during the observation period also remained stable with a slight, but statistically insignificant tendency to its increase (from 0.72 ± 0.07 to 0.75 ± 0.09; t = 37.5, p > 0.05). One patient was excluded from the study after 6 months of observation due to development of an allergic skin reaction (presumably to the components of a nutraceutical). In the vast majority of patients (97.1%), no significant side effects of therapy were observed, the nutraceutical regimen was comfortable. One more patient was excluded from the study (after 3 months) due to his failure to appear for next follow-up examination.Conclusion. The use of Retinorm ophthalmonutraceutical can stabilize the manifestations of AMD (AREDS-2–3) in 93.9 % of patients with follow-up periods of up to 12 months. Repeated courses of therapy in 97.1 % of patients are not accompanied by significant side effects, and the regimen for taking ophthalmonutraceuticals is characterized by patients as comfortable.

show abstract

Efficacy and Safety of Nutraceutical Support in Age-Related Macular Degeneration Patients

et al. 2023

View full text Add to dashboard Cite

Purpose: to assess the possibilities of nutraceutical support in AREDS-3 category age-related macular degeneration (AMD) patients.Patients and methods. The study included 30 AREDS-3 category AMD patients (30 eyes) aged 69.2 ± 5.7 years (12 men, 18 women). As the ophthalmic nutraceutical, the biological active supplement was used, including vitamins E, B1, B2, B3, B9, B12, C, lutein, zeaxantin, lycopene, resveratrol, beta-carotene, coenzyme Q10, copper, zinc, selenium (Oftolik®; 1 capsule, 2 times a day). Follow-up period: 12–16 months (6–8 courses of therapy). All those observed underwent: standard ophthalmological examination; fundus photo registration (Nidek); OCT (Opto-Vue); OCT-angiography (Zeiss); possible systemic side effects registration. The main criterion for nutraceutical support effectiveness was stabilization of AMD manifestation. The significance of a possible increase in number and (or) size of drusen (with the AREDS-3 category), as well as the appearance of patients with AMD of the AREDS-4 category, was assessed using the Pearson γ2 test. An additional criterion was the maximum corrected visual acuity (MCVA) stabilization. The mean and its standard deviation (M ± s) were calculated, the significance of differences was assessed using the Wilcoxon’s T-test.Results. None of the eyes included in the study showed progression from the AMD AREDS-3 category to AREDS-4. In one eye (3.33 %), an increase in the number of drusen was recorded; in 29 eyes (96.67 %), the number and size of drusen remained stable. These changes were not statistically significant (γ2 = 1.017; p = 0.314; p > 0.05). MCVA during the follow-up period remained stable with a slight but statistically insignificant trend towards its increase (from 0.69 ± 0.096 to 0.71 ± 0.07; Temp = 165, p > 0.05). In all observed patients, the tolerability of ophthalmonutraceutical was good, no significant side effects were recorded.Conclusion. Nutraceutical support prevented the progression of AMD from AREDS-3 to AREDS-4 during follow-up of 12–16 months. In the vast majority of patients (96.67 %), manifestation of AMD within the AREDS-3 category remained stable. After 6-8 courses of therapy, no significant side effects of nutraceutical support were recorded.

show abstract

Efficacy of conservative treatment in patients with dry form of age-related macular degeneration

Cited by 3 publications

References 12 publications

Fundus autofluorescence and multicolour imaging comparison in assessing disease severity in patients suffering from geographic atrophy. A case series analysis

Fundus autofluorescence and multicolour imaging comparison in assessing disease severity in patients suffering from geographic atrophy. A case series analysis

Our Experience of Nutraceutical Effects in Age-Related Macular Degeneration

Efficacy and Safety of Nutraceutical Support in Age-Related Macular Degeneration Patients

Contact Info

Product

Resources

About